Bristol Myers Squibb

News

CAR-T earlier use backing in multiple myeloma

CAR-Ts set to move earlier in multiple myeloma therapy

FDA advisors have said that two BCMA-targeted CAR-T therapies can be used earlier in the treatment pathway for multiple myeloma, setting up FDA approvals for use in a broa

News

Pfizer’s ulcerative colitis drug Velsipity gets EU okay

The European Commission has approved Pfizer’s S1P receptor modulator Velsipity as a treatment for ulcerative colitis (UC), raising the pressure on Bristol-Myers Squibb’s f

News

Jazz buys KRAS inhibitors from Redx in $880m deal

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma,

News

BMS' subcutaneous Opdivo clears first phase 3 trial

Bristol-Myers Squibb is getting closer to offering a subcutaneous version of its cancer immunotherapy Opdivo to patients after it matched the current intravenous formulati

News

BMS eyes first-line colorectal cancer use for Opdivo-Yervoy

The combination of Bristol-Myers Squibb’s Opdivo and Yervoy cancer immunotherapies is on track for approval as a first-line therapy for patients with a particular form of

News

Cytokinetics rockets on positive heart drug trial

Shares in US biotech Cytokinetics have popped after a report that its aficamten drug improved symptoms in people with a rare and progressive form of heart disease.

CAR-Ts set to move earlier in multiple myeloma therapy

Pfizer’s ulcerative colitis drug Velsipity gets EU okay

Jazz buys KRAS inhibitors from Redx in $880m deal

BMS' subcutaneous Opdivo clears first phase 3 trial

BMS eyes first-line colorectal cancer use for Opdivo-Yervoy

Cytokinetics rockets on positive heart drug trial

J&J's multiple myeloma duo aces phase 3 trial

Discover a new era of healthcare panel engagement: Grounded ...

Bristol Myers Squibb

Editor's Picks